Edinburgh-based life sciences firm Cytomos has made three C-suite appointments as the firm gears up for its next stage of growth.

David Rigterink joins the scale-up as CEO and is appointed to the Board while Dr Lindsay Fraser joins as Chief Scientific Officer (CSO).

In addition, Gordon Sharp has been promoted to interim Chief Technology Officer as part of a new-look executive team.

Prior to joining Cytomos, David Rigterink led business development for biopharma startup Single Use Support, which attracted substantial investment from Danaher Life Sciences Group in 2020.

Dr Fraser joins the executive team to direct the company’s ambitious scientific programme. Meanwhile, Gordon Sharp will lead the company’s complex instrument design programme and strengthen its IP portfolio.

Having joined Cytomos as Principal Design Engineer in 2016, Gordon brings more than 30 years experience in the microelectronic and instrumentation industries.

Commenting on the appointments, Cytomos Chairman Dr Alan Raymond said: “The appointments of David, Lindsay and Gordon add considerable experience and expertise to our first-class team of biopharma professionals.

“With our new Executive team and funding in place, Cytomos is well positioned to accelerate its pace of growth and advance the development of our novel process analytical technology platform.”

Cytomos’ proprietary platform, CytomoDielectric Spectroscopy (CDS), provides scientists with a low-cost, portable and scalable approach to cell analysis.

The technology has been designed specifically to help accelerate the development of novel therapies.

Supporting growth at Cytomos

The appointments follow a successful £1.6 million funding round for Cytomos to progress the development of its novel cell analysis platform.

The investment round was led by existing investor Archangels with participation from Scottish Enterprise and Old College Capital.

The newly appointed Executive team will help drive the company forward during this next growth stage, which includes the development of the CDS platform, the conceptual design of in-line GMP chip sensors, and relocation to a larger integrated HQ with office and laboratory space.

Recommended

• AND Digital announces new tech for good partnership
• Archangels generates up to £1.4bn for Scottish economy
• New hires boost Reactec senior team

David Rigterink, CEO at Cytomos, said: “The opportunity to lead such a talented team at such a critical stage in the company’s development is a huge privilege.

“Through the development of our CDS technology platform, Cytomos has a powerful tool which will help the scientific community to bring novel therapies to market faster and radically reduce costs by making game-changing decisions earlier.

“I’m excited about what the future holds for Cytomos as we embark on our next phase of growth.”

Get the latest news from DIGIT direct to your inbox

Our newsletter covers the latest technology and IT news from Scotland and beyond, as well as in-depth features and exclusive interviews with leading figures and rising stars.

To subscribe, click here.